MediHoney for Radiation Dermatitis
Completed · Not applicable
Conditions studied: Breast Cancer, Radiation Dermatitis
In brief
The aim of this study is to compare the effects of Medihoney and Hydrophor on radiation dermatitis reactions in a group of women undergoing radiation therapy for breast cancer. It is hoped that the outcome of this pilot study will provide evidence supporting the use of Medihoney in preventing and treating radiation dermatitis as well as sufficient preliminary data to expand this study to larger, federally funded research (R01) looking at the beneficial aspects of Medihoney across a spectrum of radiation dermatitis and mucositis in several disease settings.
Key facts
- Study ID
- NCT02234479
- Run by
- University of Maryland, Baltimore
- People needed
- 34
- Starts
- 2014-06-01
- Expected to finish
- 2014-12-01
- Last updated by the study team
- 2020-03-18
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Breast cancer treated with either lumpectomy or mastectomy (with or without reconstruction).
- The patient must be female.
- Radiation therapy planned to whole breast/chestwall area (can include lymph node radiation; conventional 3D radiation, IMRT/IGRT, and hypofractionation are all allowed).
- Age ≥ 18 years old.
You may not qualify if…
- Previous radiation therapy to chest area that would result in overlapping radiation fields.
- Wound care issues.
- Patients undergoing concurrent cytotoxic chemotherapy and radiation therapy (concurrent Herceptin and/or tamoxifen/aromatase inhibitors and RT is allowed).
- Patients receiving HDR (savi or mammosite) brachytherapy treatments.
- Patients with an allergy and/or sensitivity to Hydrophor, honey, and/or Medihoney.
- Immunocompromised status.
- Age < 18 years old.
Where it is running
- University of Maryland — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.